FSMP

Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe

Retrieved on: 
Thursday, March 16, 2023

Developed with the Company’s proprietary Physiomimic Technology™ platform, the PKU GOLIKE family of products are next-generation, prolonged-release amino acid medical foods for the dietary management of phenylketonuria (PKU).

Key Points: 
  • Developed with the Company’s proprietary Physiomimic Technology™ platform, the PKU GOLIKE family of products are next-generation, prolonged-release amino acid medical foods for the dietary management of phenylketonuria (PKU).
  • The new PKU GOLIKE BARs come in tropical and red fruit flavors and contain natural ingredients and real fruit.
  • To learn more about the features of the new PKU GOLIKE BARs, watch the following video: https://youtu.be/tI_UxCRCedw
    “Our team has spent the past four years conducting focus groups and qualitative research, working directly with patients, caregivers and healthcare providers in the PKU community to develop the new PKU GOLIKE BARs,” said Jack Weinstein, chief executive officer of Relief Therapeutics.
  • “The new PKU GOLIKE BARs were developed with patients and for patients to address the needs expressed by patients.

Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars

Retrieved on: 
Tuesday, February 28, 2023

Relief Therapeutics Recognizes Rare Disease Day and Announces U.S.

Key Points: 
  • Relief Therapeutics Recognizes Rare Disease Day and Announces U.S.
  • Availability of New PKU GOLIKE Bars
    Relief Therapeutics Recognizes Rare Disease Day and Announces U.S.
  • My oldest son Riccardo was born with PKU, a rare, lifelong metabolic disease I had never heard of before his birth.
  • More flavors of the bars and other forms of PKU GOLIKE are currently in development.

Bo'ao Winhealth Rare Disease Medical Center and Ali Health Jointly Launched the "Global Drug Information Platform for Rare Diseases"

Retrieved on: 
Monday, September 27, 2021

Jointly built by Bo'ao Winhealth Rare Disease Medical Center and Ali Health, the Platform aims at addressing the challenges of unavailability and unaffordability of the overseas innovative therapies facing the Chinese patients with rare diseases.

Key Points: 
  • Jointly built by Bo'ao Winhealth Rare Disease Medical Center and Ali Health, the Platform aims at addressing the challenges of unavailability and unaffordability of the overseas innovative therapies facing the Chinese patients with rare diseases.
  • "The Global Drug Information Platform for Rare Diseases is an effective exploration by multiple parties for the construction of support system for rare diseases.
  • The special policy of Boao Lecheng Pilot Zone and Bo'ao Winhealth Rare Disease Medical Center offer hope for patients.
  • For more information, please follow "Bo'ao Winhealth Rare Disease Medical Center" on Wechat.